Centessa Pharmaceuticals PLC ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $6.39
- Today's High:
- $6.72
- Open Price:
- $6.68
- 52W Low:
- $3
- 52W High:
- $6.09
- Prev. Close:
- $6.56
- Volume:
- 27223
Company Statistics
- Market Cap.:
- $426.43 million
- Book Value:
- 3.084
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -25.98%
- Return on Equity TTM:
- -54.93%
Company Profile
Centessa Pharmaceuticals PLC ADR had its IPO on 2021-05-28 under the ticker symbol CNTA.
The company operates in the Healthcare sector and Biotechnology industry. Centessa Pharmaceuticals PLC ADR has a staff strength of 82 employees.
Stock update
Shares of Centessa Pharmaceuticals PLC ADR opened at $6.68 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $6.39 - $6.72, and closed at $6.72.
This is a +2.44% increase from the previous day's closing price.
A total volume of 27,223 shares were traded at the close of the day’s session.
In the last one week, shares of Centessa Pharmaceuticals PLC ADR have slipped by -12.5%.
Centessa Pharmaceuticals PLC ADR's Key Ratios
Centessa Pharmaceuticals PLC ADR has a market cap of $426.43 million, indicating a price to book ratio of 0.9842 and a price to sales ratio of 0.
In the last 12-months Centessa Pharmaceuticals PLC ADR’s revenue was $0 with a gross profit of $0 and an EBITDA of $-204782000. The EBITDA ratio measures Centessa Pharmaceuticals PLC ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Centessa Pharmaceuticals PLC ADR’s operating margin was 0% while its return on assets stood at -25.98% with a return of equity of -54.93%.
In Q1, Centessa Pharmaceuticals PLC ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Centessa Pharmaceuticals PLC ADR’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.24 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Centessa Pharmaceuticals PLC ADR’s profitability.
Centessa Pharmaceuticals PLC ADR stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.9343. Its price to sales ratio in the trailing 12-months stood at 0.
Centessa Pharmaceuticals PLC ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $403.86 million
- Total Liabilities
- $29.69 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $88000
- Dividend Payout Ratio
- 0%
Centessa Pharmaceuticals PLC ADR ended 2024 with $403.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $403.86 million while shareholder equity stood at $293.26 million.
Centessa Pharmaceuticals PLC ADR ended 2024 with $0 in deferred long-term liabilities, $29.69 million in other current liabilities, 266000.00 in common stock, $-652574000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $259.99 million and cash and short-term investments were $346.23 million. The company’s total short-term debt was $398,000 while long-term debt stood at $71.60 million.
Centessa Pharmaceuticals PLC ADR’s total current assets stands at $384.33 million while long-term investments were $0 and short-term investments were $86.24 million. Its net receivables were $23.39 million compared to accounts payable of $14.37 million and inventory worth $0.
In 2024, Centessa Pharmaceuticals PLC ADR's operating cash flow was $0 while its capital expenditure stood at $88000.
Comparatively, Centessa Pharmaceuticals PLC ADR paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $6.72
- 52-Week High
- $6.09
- 52-Week Low
- $3
- Analyst Target Price
- $5.9
Centessa Pharmaceuticals PLC ADR stock is currently trading at $6.72 per share. It touched a 52-week high of $6.09 and a 52-week low of $6.09. Analysts tracking the stock have a 12-month average target price of $5.9.
Its 50-day moving average was $6.95 and 200-day moving average was $4.81 The short ratio stood at 10.88 indicating a short percent outstanding of 0%.
Around 185.9% of the company’s stock are held by insiders while 7704.7% are held by institutions.
Frequently Asked Questions About Centessa Pharmaceuticals PLC ADR
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.